Clinical trials on Pulmonary embolism

Pulmonary Embolism: An Overview

Pulmonary embolism (PE) is a serious, potentially life-threatening condition that occurs when a blood clot travels to the lungs. This clot, usually originating from the deep veins of the legs in a condition known as deep vein thrombosis (DVT), blocks one of the pulmonary arteries, disrupting blood flow to the lungs. The severity of PE can vary greatly, from no symptoms to sudden, catastrophic death. The key to managing this condition lies in prompt diagnosis and treatment.

Signs, Symptoms, and Risk Factors

The clinical presentation of PE can be nonspecific, but common symptoms include shortness of breath, chest pain that may become worse when breathing in, cough, and sometimes blood in the sputum. Factors that increase the risk of developing PE include prolonged immobility, recent surgery, cancer, and a history of DVT or PE. Preventative measures, such as anticoagulant medication and physical activity, are crucial for those at high risk.

Diagnosis and Treatment

Diagnosing PE involves a combination of medical history, physical examination, and diagnostic tests, including D-dimer blood tests, ultrasound of the legs, CT pulmonary angiography, and sometimes ventilation-perfusion (V/Q) scans. Treatment typically involves anticoagulant medications to prevent further clotting, and in severe cases, thrombolytic therapy to dissolve the clot. In some situations, surgical intervention may be necessary to remove the clot directly or to insert a filter in the vena cava to catch future clots before they reach the lungs.

  • CT-EU-00111193

    Understanding Catheter Interventions for Severe Pulmonary Embolism: A Multicenter Study

    The Registry of Catheter Intervention in Pulmonary Embolism is a comprehensive study that focuses on patients who have been admitted for moderate to high-risk or high-risk pulmonary embolism, as defined by the 2019 European Society of Cardiology guidelines. This study is unique because it looks at cases both from the past, starting in 2014, and moving forward from 2018, making it a blend of retrospective and prospective research. The main goal of this study is to closely examine how acute pulmonary embolism is managed using various percutaneous (minimally invasive) interventions. By participating, you’ll be contributing valuable information that will help understand the safety and effectiveness of these treatments. One of the key aspects the study aims to measure is the rate of all cause-death during hospital admission, which is expected to be within 10 days. This information is crucial for improving future treatment strategies for patients facing similar health challenges.

  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    • Anticoagulation with heparin
  • Comparison of two drugs in the treatment of venous thromboembolism

    The study compares abelacimab and dalteparin in treating blood clot issues in patients with gastrointestinal or genitourinary cancers. It’s open to adults, focusing on those without plans for curative surgery. Abelacimab is given monthly, and dalteparin daily, over six months. It assesses clot recurrence, bleeding risks, and treatment continuation. The goal is to find safer, effective blood clot treatments for cancer patients, improving their care and outcomes.

    • Abelacimab
    • Dalteparin
  • Thrombolysis therapy in treating acute Pulmonary Embolism

    This study aims to evaluate a reduced dose of thrombolytic treatment for patients with intermediate-high-risk acute pulmonary embolism. It compares the new treatment approach with a placebo to assess effectiveness and safety. The study’s focus is on reducing the risk of major and intracranial bleeding associated with full-dose thrombolytic treatment. Participants will receive either the experimental treatment or a placebo, alongside standard anticoagulation therapy. The primary goal is to determine the efficacy and safety of the reduced dosage at day 30, with long-term follow-up assessments planned. This research is crucial for improving treatment options for patients with this serious lung condition.

    • Alteplase
  • Alteplase low-dose trial for acute pulmonary embolism care

    In this trial, participants with a specific type of lung clot called intermediate-high-risk acute pulmonary embolism are given a lower dose of Alteplase, a medication that dissolves blood clots. The study compares the effects of this reduced dose to a non-active placebo to see if it can reduce clot-related risks without increasing bleeding, especially in the brain. The treatment involves a short intravenous injection and is tested alongside standard anticoagulants. Success is measured by patient health 30 days after the treatment, with an eye on long-term outcomes like survival and heart function up to two years later.

    • Alteplase